comparemela.com

Patricio Murphy News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Globalization: As Fragile And Irreplaceable As Ever

The coronavirus plague has blatantly conveyed the reality, for better or worse, of a single, globalized space. When the pandemic dies down, expect new socio-cultural dynamics, and a redefinition of the state's role.

Recognizing And Reviving Argentina s Indigenous Languages

Argentina prepares for strict lockdown as COVID cases soar

Argentina prepares for strict lockdown as COVID cases soar dw.com 3 hrs ago Beatrice Christofaro Argentina is going into a short, total lockdown to break its second coronavirus wave. The country hit record numbers of daily infections and deaths this week. © Patricio Murphy/ZUMAPRESS/picture alliance ICUs in Argentina are hitting their limits as cases soar Starting on Saturday, most Argentines will be allowed out only from 6 a.m. to 6 p.m. local time, and they will have to stay close to their homes. Schools and non-essential businesses will be closed. Social, religious and sporting events will be banned. With thiscircuit breaker lockdown, which will last until May 31, the Argentine government hopes to halt skyrocketing coronavirus infections. There will be another total lockdown on the weekend of June 5 and 6.

Lancet study finds Sputnik V more than 91% effective against Covid-19, 100% in preventing severe cases -- Health & Wellness -- Sott net

© Global Look Press / Patricio Murphy Sputnik V vaccine In a major breakthrough for Russia s Sputnik V Covid-19 vaccine, the prestigious British medical journal The Lancet has published preliminary Phase III trial results showing it is highly effective - notably, for all age groups. Comment: This is important because the experimental and unproven Pfizer and Moderna vaccines have little to no data on the efficacy for the at risk age groups. Data from 19,866 volunteers - 4,902 of whom were in the placebo group - showed that Sputnik V had an overall efficacy of 91.6 percent, rising to 91.8 percent among the group of 2,144 volunteers over the age of 60, according to the interim results of the Phase III clinical trial published in the

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.